This article is more than 5 years old. Information may no longer be current.
EndoBarrier improves glycemic control in patients with diabetes, obesity
EndoBarrier, an endoscopic device that mimics the small bowel mechanisms of Roux-en-Y gastric bypass, improved glycemic control and insulin resistance in patients with type 2 diabetes and obesity, according to a meta-analysis published in Diabetes Care.
Pichamol Jirapinyo, MD, of the division of gastroenterology, hepatology and endoscopy at Brigham and Women’s Hospital, and colleagues wrote that previous studies already have shown the efficacy of EndoBarrier (duodenal-jejunal bypass liner, GI Dynamics) at inducing weight loss. Hence, they set out to test the effectiveness of the device on glycemic control in patients with type 2 diabetes.
“Given a rising pandemic of obesity and diabetes, [duodenal-jejunal bypass liner (DJBL)] may offer a highly effective treatment option for this patient population,” Jirapinyo said in a press release.
Jirapinyo and colleagues included data from 17 studies that evaluated DJBL in their analysis. The primary outcomes were change in HbA1c and homeostasis model assessment of insulin resistance (HOMA-IR).
The investigators found that patients who underwent DJBL therapy experienced a 1.3% reduction in HbA1c (95% CI, 1-1.6) and HOMA-IR decreased by 4.6 (95% CI, 2.9-6.3). When researchers compared these patients with individuals who were treated with medicine alone, they found the DJBL patients experienced a 0.9% reduction in HbA1c (95% CI, 0.5-1.3).
Additionally, patients who received DJBL also experienced improvement in weight loss, according to the press release.
“The results confirm that EndoBarrier produces a significant reduction in HbA1c and weight, significantly reduces insulin resistance and creates a hormonal effect similar in many respects to gastric bypass,” Scott Schorer, president and CEO of GI Dynamics said in the press release. “This data clearly shows a very favorable treatment effect with significant treatment durability and a positive benefit-risk profile.” – by Alex Young
Disclosures: Jirapinyo reports no relevant financial disclosures. Schorer is employed by GI Dynamics. Please see the full study for the authors’ relevant financial disclosures.